Experimental cocktail aims to tackle tough blood cancers

NCT ID NCT06207123

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called LP-118 combined with three existing cancer medicines (ponatinib, vincristine, and dexamethasone) in adults with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to find a safe dose and see if the combination can put the cancer into remission. The trial is small, with 15 participants, and is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LP-118 (experimental drug) combined with ponatinib, vincristine, and dexamethasone
What this could lead to: If successful, this could provide a new treatment option for people with hard-to-treat T-cell leukemia or lymphoma.
What could go wrong: This is an early-phase trial with only 15 participants, so results may not apply widely. The drug combination may cause serious side effects or fail to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia acute lymphoblastic leukemia lymphoblastic lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma T-cell acute lymphoblastic leukemia T-lymphoblastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA LYMPHOBLASTIC LEUKEMIA LYMPHOBLASTIC LYMPHOMA

Contacts and locations

Show contact details

Locations

University of Chicago Medicine Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60615, United States
University of Rochester Medical Center, Wilmot Cancer Center
RECRUITING

Rochester, New York, 14642, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.